207 related articles for article (PubMed ID: 25173703)
1. Radioligand development for molecular imaging of the central nervous system with positron emission tomography.
Honer M; Gobbi L; Martarello L; Comley RA
Drug Discov Today; 2014 Dec; 19(12):1936-44. PubMed ID: 25173703
[TBL] [Abstract][Full Text] [Related]
2. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand.
Zhang L; Villalobos A; Beck EM; Bocan T; Chappie TA; Chen L; Grimwood S; Heck SD; Helal CJ; Hou X; Humphrey JM; Lu J; Skaddan MB; McCarthy TJ; Verhoest PR; Wager TT; Zasadny K
J Med Chem; 2013 Jun; 56(11):4568-79. PubMed ID: 23651455
[TBL] [Abstract][Full Text] [Related]
3. Carbon-11 and fluorine-18 chemistry devoted to molecular probes for imaging the brain with positron emission tomography.
Dollé F
J Labelled Comp Radiopharm; 2013; 56(3-4):65-7. PubMed ID: 24285311
[TBL] [Abstract][Full Text] [Related]
4. Radioligands for the dopamine receptor subtypes.
Prante O; Maschauer S; Banerjee A
J Labelled Comp Radiopharm; 2013; 56(3-4):130-48. PubMed ID: 24285319
[TBL] [Abstract][Full Text] [Related]
5. Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds.
Andersson JD; Pierson ME; Finnema SJ; Gulyás B; Heys R; Elmore CS; Farde L; Halldin C
Nucl Med Biol; 2011 Feb; 38(2):261-72. PubMed ID: 21315282
[TBL] [Abstract][Full Text] [Related]
6. Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers?
Joshi EM; Need A; Schaus J; Chen Z; Benesh D; Mitch C; Morton S; Raub TJ; Phebus L; Barth V
ACS Chem Neurosci; 2014 Dec; 5(12):1154-63. PubMed ID: 25247893
[TBL] [Abstract][Full Text] [Related]
7. Determination of plasma protein binding of positron emission tomography radioligands by high-performance frontal analysis.
Amini N; Nakao R; Schou M; Halldin C
J Pharm Biomed Anal; 2014 Sep; 98():140-3. PubMed ID: 24922085
[TBL] [Abstract][Full Text] [Related]
8. Radioligands targeting purinergic P2X7 receptor.
Zheng QH
Bioorg Med Chem Lett; 2020 Jun; 30(12):127169. PubMed ID: 32273217
[TBL] [Abstract][Full Text] [Related]
9. A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-ethyl-2-[11C]methyl-6-quinolinyl)(cis- 4-methoxycyclohexyl)methanone.
Huang Y; Narendran R; Bischoff F; Guo N; Zhu Z; Bae SA; Lesage AS; Laruelle M
J Med Chem; 2005 Aug; 48(16):5096-9. PubMed ID: 16078827
[TBL] [Abstract][Full Text] [Related]
10. Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).
Patel S; Schmidt K; Hesterman J; Hoppin J
Mol Imaging Biol; 2017 Jun; 19(3):348-356. PubMed ID: 28417265
[TBL] [Abstract][Full Text] [Related]
11. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.
Horti AG; Van Laere K
Curr Pharm Des; 2008; 14(31):3363-83. PubMed ID: 19075713
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceutical chemistry for positron emission tomography.
Li Z; Conti PS
Adv Drug Deliv Rev; 2010 Aug; 62(11):1031-51. PubMed ID: 20854860
[TBL] [Abstract][Full Text] [Related]
13. Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography.
Passchier J; Gentile G; Porter R; Herdon H; Salinas C; Jakobsen S; Audrain H; Laruelle M; Gunn RN
Synapse; 2010 Jul; 64(7):542-9. PubMed ID: 20196141
[TBL] [Abstract][Full Text] [Related]
14. Derivatives of (-)-7-methyl-2-(5-(pyridinyl)pyridin-3-yl)-7-azabicyclo[2.2.1]heptane are potential ligands for positron emission tomography imaging of extrathalamic nicotinic acetylcholine receptors.
Gao Y; Horti AG; Kuwabara H; Ravert HT; Hilton J; Holt DP; Kumar A; Alexander M; Endres CJ; Wong DF; Dannals RF
J Med Chem; 2007 Aug; 50(16):3814-24. PubMed ID: 17629263
[TBL] [Abstract][Full Text] [Related]
15. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development.
Halldin C; Gulyás B; Farde L
Curr Pharm Des; 2001 Dec; 7(18):1907-29. PubMed ID: 11772357
[TBL] [Abstract][Full Text] [Related]
16. Brain radioligands--state of the art and new trends.
Halldin C; Gulyás B; Langer O; Farde L
Q J Nucl Med; 2001 Jun; 45(2):139-52. PubMed ID: 11476163
[TBL] [Abstract][Full Text] [Related]
17. Radiosynthesis and evaluation of new α1-adrenoceptor antagonists as PET radioligands for brain imaging.
Airaksinen AJ; Finnema SJ; Balle T; Varnäs K; Bang-Andersen B; Gulyás B; Farde L; Halldin C
Nucl Med Biol; 2013 Aug; 40(6):747-54. PubMed ID: 23810488
[TBL] [Abstract][Full Text] [Related]
18. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development.
Lever JR
Curr Pharm Des; 2007; 13(1):33-49. PubMed ID: 17266587
[TBL] [Abstract][Full Text] [Related]
19. Development of new radiopharmaceuticals for imaging monoamine oxidase B.
Vasdev N; Sadovski O; Moran MD; Parkes J; Meyer JH; Houle S; Wilson AA
Nucl Med Biol; 2011 Oct; 38(7):933-43. PubMed ID: 21982565
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological prerequisites for PET ligands and practical issues in preclinical PET research.
Ametamey SM; Honer M
Ernst Schering Res Found Workshop; 2007; (62):317-27. PubMed ID: 17172161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
